1
Kevin Rodzinak
DUDKIN Vadim, FRALEY Mark E, ARRINGTON Kenneth L, LAYTON Mark E, RODZINAK Kevin J, PERO Joseph E, REIF Alexander J: Modulateurs allostériques positifs de mglur2, Positive allosteric modulators of mglur2. Merck Sharp & Dohme, DUDKIN Vadim, FRALEY Mark E, ARRINGTON Kenneth L, LAYTON Mark E, RODZINAK Kevin J, PERO Joseph E, REIF Alexander J, February 16, 2012: WO/2012/021382 (16 worldwide citation)

The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involve ...


2
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael J Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck Sharp & Dohme, Matthew A Leff, David A Mutard, August 30, 2011: US08008317 (4 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


3
Kevin Rodzinak
Philip E Sanderson, Mark E Layton, Kevin J Rodzinak: Inhibitors of AKT activity. Merck Sharp & Dohme, Matthew A Leff, Yong Zhao, David A Muthard, May 1, 2012: US08168652 (3 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


4
Kevin Rodzinak
Vadim Y Dudkin, Mark E Fraley, Kenneth L Arrington, Mark E Layton, Alexander J Reif, Kevin J Rodzinak, Joseph E Pero: Positive allosteric modulators of MGLUR2. Merck Sharp & Dohme, Keith D MacMillan, John C Todaro, March 31, 2015: US08993779 (1 worldwide citation)

The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involve ...


5
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas D P Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt activity. Merck Sharp & Dohme, Matthew A Leff, David A Muthard, March 22, 2011: US07910561 (1 worldwide citation)

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


6

7

8
Kevin Rodzinak
Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing: Inhibiteurs de lactivite akt, Inhibitors of akt activity. Merck & Co, Merck Sharp & Dohme, Gowling Lafleur Henderson, February 8, 2011: CA2610888

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


9

10


Click the thumbnails below to visualize the patent trend.